Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Bacterial Agents | 14 | 2019 | 788 | 2.830 |
Why?
|
Vancomycin | 10 | 2016 | 73 | 2.420 |
Why?
|
Clostridium Infections | 10 | 2022 | 124 | 2.390 |
Why?
|
Hematopoietic Stem Cell Transplantation | 16 | 2023 | 890 | 2.010 |
Why?
|
Antifungal Agents | 13 | 2020 | 120 | 1.960 |
Why?
|
Enterocolitis, Pseudomembranous | 8 | 2019 | 52 | 1.940 |
Why?
|
Herpes Zoster | 5 | 2019 | 79 | 1.870 |
Why?
|
Triazoles | 10 | 2018 | 102 | 1.690 |
Why?
|
Aminoglycosides | 7 | 2013 | 32 | 1.640 |
Why?
|
Herpes Zoster Vaccine | 3 | 2019 | 10 | 1.280 |
Why?
|
Invasive Fungal Infections | 5 | 2020 | 10 | 1.280 |
Why?
|
Antiviral Agents | 10 | 2021 | 478 | 1.240 |
Why?
|
Nitriles | 5 | 2018 | 160 | 1.060 |
Why?
|
Immunocompromised Host | 12 | 2021 | 142 | 1.050 |
Why?
|
Pyridines | 6 | 2018 | 315 | 1.020 |
Why?
|
Organophosphonates | 3 | 2018 | 50 | 0.820 |
Why?
|
Cytosine | 3 | 2018 | 128 | 0.770 |
Why?
|
Organ Transplantation | 3 | 2019 | 276 | 0.720 |
Why?
|
Double-Blind Method | 15 | 2023 | 1719 | 0.710 |
Why?
|
Cytomegalovirus Infections | 5 | 2019 | 148 | 0.650 |
Why?
|
Mycoses | 3 | 2020 | 46 | 0.610 |
Why?
|
Peptides, Cyclic | 2 | 2016 | 44 | 0.610 |
Why?
|
Thiazoles | 2 | 2014 | 128 | 0.580 |
Why?
|
Adenosine Monophosphate | 3 | 2021 | 27 | 0.560 |
Why?
|
Lipopeptides | 2 | 2016 | 17 | 0.560 |
Why?
|
Alanine | 3 | 2021 | 83 | 0.550 |
Why?
|
Valine | 1 | 2016 | 62 | 0.550 |
Why?
|
Herpesvirus 3, Human | 1 | 2016 | 41 | 0.550 |
Why?
|
Adult | 43 | 2022 | 26607 | 0.540 |
Why?
|
Drugs, Investigational | 1 | 2016 | 39 | 0.540 |
Why?
|
Acyclovir | 1 | 2016 | 108 | 0.540 |
Why?
|
Middle Aged | 40 | 2024 | 25974 | 0.530 |
Why?
|
Aged | 29 | 2020 | 19165 | 0.510 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 173 | 0.500 |
Why?
|
Transplant Recipients | 6 | 2023 | 137 | 0.480 |
Why?
|
Male | 51 | 2024 | 42411 | 0.470 |
Why?
|
Humans | 68 | 2024 | 89357 | 0.450 |
Why?
|
Invasive Pulmonary Aspergillosis | 3 | 2018 | 8 | 0.440 |
Why?
|
Daptomycin | 1 | 2013 | 3 | 0.440 |
Why?
|
Minocycline | 1 | 2013 | 15 | 0.440 |
Why?
|
Treatment Outcome | 21 | 2020 | 8241 | 0.440 |
Why?
|
Edetic Acid | 1 | 2013 | 42 | 0.430 |
Why?
|
Biofilms | 1 | 2013 | 46 | 0.420 |
Why?
|
Female | 42 | 2020 | 46202 | 0.420 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 1047 | 0.400 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 78 | 0.400 |
Why?
|
Actinomycetales | 1 | 2011 | 5 | 0.390 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2011 | 16 | 0.390 |
Why?
|
Neoplasms | 2 | 2019 | 3041 | 0.380 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2020 | 24 | 0.370 |
Why?
|
Administration, Oral | 6 | 2018 | 682 | 0.370 |
Why?
|
HIV Infections | 4 | 2013 | 840 | 0.370 |
Why?
|
Ethanol | 1 | 2013 | 250 | 0.360 |
Why?
|
Aged, 80 and over | 10 | 2018 | 6811 | 0.350 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2013 | 219 | 0.350 |
Why?
|
Gastrointestinal Tract | 1 | 2011 | 191 | 0.330 |
Why?
|
Respiratory Tract Infections | 2 | 2020 | 106 | 0.330 |
Why?
|
Hematologic Neoplasms | 3 | 2020 | 343 | 0.320 |
Why?
|
Administration, Intravenous | 5 | 2020 | 57 | 0.310 |
Why?
|
Mucormycosis | 4 | 2018 | 15 | 0.300 |
Why?
|
Young Adult | 9 | 2018 | 6312 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 838 | 0.270 |
Why?
|
Acetates | 2 | 2017 | 65 | 0.270 |
Why?
|
Diarrhea | 4 | 2015 | 182 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 319 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 304 | 0.250 |
Why?
|
Adolescent | 13 | 2018 | 9263 | 0.250 |
Why?
|
Legionellosis | 1 | 2024 | 6 | 0.240 |
Why?
|
Legionella | 1 | 2024 | 16 | 0.240 |
Why?
|
Quinazolines | 2 | 2017 | 221 | 0.240 |
Why?
|
Vaccination | 2 | 2019 | 274 | 0.240 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2003 | 8 | 0.230 |
Why?
|
Transplantation, Homologous | 4 | 2016 | 996 | 0.220 |
Why?
|
Pneumococcal Infections | 1 | 2023 | 47 | 0.220 |
Why?
|
Cytomegalovirus | 3 | 2018 | 78 | 0.220 |
Why?
|
Vaccines, Inactivated | 2 | 2019 | 29 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2013 | 175 | 0.200 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 203 | 0.200 |
Why?
|
Mycobacterium chelonae | 1 | 2021 | 4 | 0.190 |
Why?
|
DNA, Viral | 3 | 2017 | 262 | 0.190 |
Why?
|
Reaction Time | 2 | 1999 | 310 | 0.190 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2021 | 27 | 0.190 |
Why?
|
Coronary Disease | 2 | 1995 | 260 | 0.180 |
Why?
|
Agammaglobulinemia | 1 | 2020 | 20 | 0.180 |
Why?
|
Betacoronavirus | 2 | 2020 | 261 | 0.180 |
Why?
|
Drug Resistance, Viral | 2 | 2019 | 48 | 0.180 |
Why?
|
Cardiomyopathies | 2 | 2017 | 264 | 0.180 |
Why?
|
Anti-HIV Agents | 2 | 1999 | 159 | 0.180 |
Why?
|
Fecal Microbiota Transplantation | 2 | 2022 | 64 | 0.170 |
Why?
|
Injection Site Reaction | 1 | 2019 | 2 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 860 | 0.170 |
Why?
|
Severity of Illness Index | 3 | 2017 | 1840 | 0.170 |
Why?
|
Recurrence | 3 | 2017 | 1144 | 0.160 |
Why?
|
Bordetella Infections | 1 | 2018 | 5 | 0.160 |
Why?
|
Aminoimidazole Carboxamide | 2 | 1995 | 7 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2011 | 784 | 0.160 |
Why?
|
Ribonucleosides | 2 | 1995 | 25 | 0.160 |
Why?
|
Bacterial Infections | 1 | 2020 | 184 | 0.160 |
Why?
|
Mycobacterium tuberculosis | 1 | 2021 | 195 | 0.160 |
Why?
|
Neutrophils | 4 | 1999 | 308 | 0.150 |
Why?
|
Psychomotor Performance | 3 | 2000 | 496 | 0.150 |
Why?
|
Coinfection | 1 | 2018 | 61 | 0.150 |
Why?
|
Diagnostic Errors | 1 | 2018 | 160 | 0.150 |
Why?
|
Renal Insufficiency | 1 | 2018 | 98 | 0.150 |
Why?
|
Chemoprevention | 1 | 2017 | 92 | 0.150 |
Why?
|
Neutropenia | 1 | 2018 | 216 | 0.140 |
Why?
|
Herpesvirus 6, Human | 1 | 2017 | 19 | 0.140 |
Why?
|
Survival Analysis | 2 | 2018 | 1534 | 0.140 |
Why?
|
Investigational New Drug Application | 1 | 2016 | 2 | 0.140 |
Why?
|
Disease Management | 1 | 2019 | 329 | 0.140 |
Why?
|
Microbial Sensitivity Tests | 3 | 2012 | 150 | 0.140 |
Why?
|
Foscarnet | 1 | 2016 | 12 | 0.140 |
Why?
|
Zygomycosis | 2 | 2007 | 3 | 0.140 |
Why?
|
Myocarditis | 1 | 2017 | 51 | 0.140 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 2415 | 0.140 |
Why?
|
Hepatitis B virus | 1 | 2016 | 44 | 0.140 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2016 | 46 | 0.140 |
Why?
|
Health Behavior | 1 | 2017 | 185 | 0.130 |
Why?
|
Hepatitis B | 1 | 2016 | 76 | 0.130 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 77 | 0.130 |
Why?
|
Mannans | 1 | 2015 | 5 | 0.130 |
Why?
|
beta-Glucans | 1 | 2015 | 5 | 0.130 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2016 | 117 | 0.130 |
Why?
|
Societies, Medical | 1 | 2019 | 575 | 0.130 |
Why?
|
Cognition | 1 | 1999 | 580 | 0.120 |
Why?
|
Candida | 2 | 2012 | 18 | 0.120 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 360 | 0.120 |
Why?
|
Opportunistic Infections | 1 | 2014 | 60 | 0.110 |
Why?
|
Tissue Plasminogen Activator | 1 | 1995 | 171 | 0.110 |
Why?
|
Multivariate Analysis | 2 | 2013 | 988 | 0.110 |
Why?
|
Vaccines, Attenuated | 1 | 2013 | 51 | 0.110 |
Why?
|
Fibrinolytic Agents | 1 | 1995 | 217 | 0.110 |
Why?
|
Histoplasmosis | 1 | 2013 | 26 | 0.110 |
Why?
|
Aspergillus | 3 | 2018 | 9 | 0.110 |
Why?
|
Clinical Medicine | 1 | 2013 | 34 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 1 | 2013 | 76 | 0.110 |
Why?
|
Drug Combinations | 1 | 2013 | 203 | 0.100 |
Why?
|
Amphotericin B | 2 | 2009 | 34 | 0.100 |
Why?
|
Enterococcus | 1 | 2012 | 35 | 0.100 |
Why?
|
Prospective Studies | 6 | 2015 | 4289 | 0.100 |
Why?
|
HIV-1 | 3 | 1998 | 166 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 895 | 0.100 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2011 | 103 | 0.090 |
Why?
|
Microbiota | 1 | 2015 | 402 | 0.090 |
Why?
|
Cross Infection | 1 | 2011 | 147 | 0.090 |
Why?
|
Mucor | 1 | 2009 | 3 | 0.090 |
Why?
|
Fungi | 3 | 2018 | 66 | 0.090 |
Why?
|
Retrospective Studies | 2 | 2021 | 9057 | 0.080 |
Why?
|
Thromboxane-A Synthase | 1 | 1989 | 4 | 0.080 |
Why?
|
Multiple Myeloma | 2 | 2018 | 330 | 0.080 |
Why?
|
Glycosides | 1 | 2008 | 20 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1989 | 91 | 0.080 |
Why?
|
Myocardial Reperfusion Injury | 1 | 1989 | 58 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 151 | 0.080 |
Why?
|
Arachidonic Acids | 1 | 1988 | 41 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2003 | 415 | 0.070 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1999 | 81 | 0.070 |
Why?
|
AIDS Dementia Complex | 2 | 1998 | 8 | 0.070 |
Why?
|
Aspergillosis | 2 | 2018 | 41 | 0.070 |
Why?
|
Feces | 3 | 2014 | 330 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 793 | 0.070 |
Why?
|
Treatment Failure | 2 | 2019 | 287 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2007 | 236 | 0.070 |
Why?
|
Fungemia | 1 | 2005 | 15 | 0.060 |
Why?
|
Child | 6 | 2022 | 7174 | 0.060 |
Why?
|
Candidiasis | 1 | 2005 | 37 | 0.060 |
Why?
|
United States | 4 | 2022 | 6989 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2011 | 892 | 0.060 |
Why?
|
Lipoproteins | 1 | 2005 | 136 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 3 | 1999 | 67 | 0.060 |
Why?
|
Incidence | 3 | 2014 | 1595 | 0.060 |
Why?
|
Endocarditis, Bacterial | 1 | 2024 | 39 | 0.060 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2004 | 51 | 0.060 |
Why?
|
Hospitalization | 2 | 2020 | 877 | 0.060 |
Why?
|
Pandemics | 2 | 2020 | 773 | 0.060 |
Why?
|
Pyrimidines | 1 | 2007 | 374 | 0.060 |
Why?
|
Graft Occlusion, Vascular | 1 | 2004 | 99 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2014 | 1942 | 0.060 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 6 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2024 | 299 | 0.060 |
Why?
|
Immunogenicity, Vaccine | 1 | 2023 | 13 | 0.060 |
Why?
|
Catheters, Indwelling | 1 | 2004 | 113 | 0.060 |
Why?
|
Pneumococcal Vaccines | 1 | 2023 | 28 | 0.060 |
Why?
|
Voriconazole | 2 | 2018 | 18 | 0.060 |
Why?
|
Patient Isolation | 1 | 2003 | 14 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2004 | 115 | 0.060 |
Why?
|
Disaster Planning | 1 | 2003 | 24 | 0.060 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 100 | 0.050 |
Why?
|
Zidovudine | 2 | 1999 | 16 | 0.050 |
Why?
|
HIV Seropositivity | 2 | 2000 | 51 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2004 | 1012 | 0.050 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2022 | 51 | 0.050 |
Why?
|
Platelet Aggregation | 2 | 1994 | 44 | 0.050 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2001 | 13 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2023 | 465 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2001 | 33 | 0.050 |
Why?
|
Secondary Prevention | 2 | 2013 | 158 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 1999 | 166 | 0.050 |
Why?
|
Child, Preschool | 4 | 2013 | 3731 | 0.050 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2001 | 73 | 0.050 |
Why?
|
Patient Acuity | 1 | 2020 | 33 | 0.050 |
Why?
|
Verbal Learning | 1 | 2000 | 29 | 0.050 |
Why?
|
Lung Transplantation | 1 | 2024 | 292 | 0.050 |
Why?
|
Respiratory System | 1 | 2020 | 116 | 0.040 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 65 | 0.040 |
Why?
|
Zalcitabine | 1 | 1999 | 2 | 0.040 |
Why?
|
Didanosine | 1 | 1999 | 2 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 1999 | 18 | 0.040 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2020 | 60 | 0.040 |
Why?
|
Biomarkers | 2 | 2016 | 1767 | 0.040 |
Why?
|
Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 1999 | 306 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2003 | 1597 | 0.040 |
Why?
|
Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
Infant | 3 | 2016 | 3160 | 0.040 |
Why?
|
Phagocytes | 1 | 1998 | 11 | 0.040 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2018 | 35 | 0.040 |
Why?
|
Cross Reactions | 1 | 2018 | 109 | 0.040 |
Why?
|
Odds Ratio | 1 | 2020 | 683 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2018 | 223 | 0.040 |
Why?
|
Mucorales | 1 | 2018 | 2 | 0.040 |
Why?
|
Choice Behavior | 1 | 1999 | 160 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 1998 | 490 | 0.040 |
Why?
|
Blood Platelets | 2 | 1989 | 150 | 0.040 |
Why?
|
Rare Diseases | 1 | 2018 | 70 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2018 | 243 | 0.040 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1999 | 492 | 0.040 |
Why?
|
Allografts | 1 | 2018 | 181 | 0.040 |
Why?
|
Dogs | 2 | 1995 | 704 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2019 | 221 | 0.040 |
Why?
|
Biopsy | 1 | 2021 | 1184 | 0.040 |
Why?
|
Memory Disorders | 1 | 1997 | 69 | 0.040 |
Why?
|
Social Isolation | 1 | 2017 | 67 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 344 | 0.040 |
Why?
|
Memory, Short-Term | 1 | 2000 | 227 | 0.040 |
Why?
|
Hepatitis B e Antigens | 1 | 2016 | 7 | 0.030 |
Why?
|
Pilot Projects | 1 | 1999 | 871 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2016 | 23 | 0.030 |
Why?
|
Hepatitis B Antibodies | 1 | 2016 | 16 | 0.030 |
Why?
|
Parturition | 1 | 2016 | 21 | 0.030 |
Why?
|
Lymphoma | 1 | 2018 | 265 | 0.030 |
Why?
|
Femoral Vein | 1 | 2016 | 39 | 0.030 |
Why?
|
Prognosis | 2 | 2015 | 3783 | 0.030 |
Why?
|
Immunization | 1 | 2016 | 160 | 0.030 |
Why?
|
Fetal Blood | 1 | 2016 | 93 | 0.030 |
Why?
|
Leukemia | 1 | 2018 | 323 | 0.030 |
Why?
|
Risk Factors | 2 | 2019 | 5499 | 0.030 |
Why?
|
Enema | 1 | 2015 | 39 | 0.030 |
Why?
|
Registries | 1 | 2020 | 784 | 0.030 |
Why?
|
Viral Load | 1 | 2016 | 145 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2016 | 2486 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2018 | 1214 | 0.030 |
Why?
|
Galactose | 1 | 2015 | 32 | 0.030 |
Why?
|
Mothers | 1 | 2016 | 142 | 0.030 |
Why?
|
Health Status | 1 | 2017 | 371 | 0.030 |
Why?
|
5,8,11,14-Eicosatetraynoic Acid | 1 | 1994 | 2 | 0.030 |
Why?
|
Placenta | 1 | 2016 | 179 | 0.030 |
Why?
|
Case-Control Studies | 1 | 1999 | 1862 | 0.030 |
Why?
|
Catalase | 1 | 1994 | 49 | 0.030 |
Why?
|
Peroxidase | 1 | 1994 | 51 | 0.030 |
Why?
|
Perfusion | 1 | 1995 | 236 | 0.030 |
Why?
|
Survival Rate | 1 | 2018 | 1901 | 0.030 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 358 | 0.030 |
Why?
|
Mental Recall | 1 | 1995 | 158 | 0.030 |
Why?
|
Animals | 5 | 2016 | 27371 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 1999 | 1714 | 0.030 |
Why?
|
Attention | 1 | 1998 | 395 | 0.030 |
Why?
|
Apoptosis | 2 | 1999 | 1717 | 0.030 |
Why?
|
Luminescent Measurements | 3 | 1999 | 62 | 0.030 |
Why?
|
Arachidonic Acid | 2 | 1994 | 63 | 0.030 |
Why?
|
Free Radicals | 2 | 1994 | 71 | 0.030 |
Why?
|
Limit of Detection | 1 | 2012 | 20 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2012 | 75 | 0.030 |
Why?
|
Canada | 1 | 2012 | 208 | 0.020 |
Why?
|
Adenosine | 1 | 1994 | 238 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 922 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2011 | 69 | 0.020 |
Why?
|
Neuropsychological Tests | 3 | 1998 | 505 | 0.020 |
Why?
|
Logistic Models | 1 | 2013 | 1213 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 2624 | 0.020 |
Why?
|
Phenylacetates | 1 | 1989 | 3 | 0.020 |
Why?
|
Rats, Inbred SHR | 1 | 1989 | 33 | 0.020 |
Why?
|
Hydralazine | 1 | 1989 | 19 | 0.020 |
Why?
|
Respiratory Burst | 2 | 1999 | 18 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2001 | 3448 | 0.020 |
Why?
|
Indomethacin | 1 | 1989 | 59 | 0.020 |
Why?
|
Pregnancy | 1 | 2016 | 3018 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 1989 | 28 | 0.020 |
Why?
|
Benzazepines | 1 | 1989 | 64 | 0.020 |
Why?
|
Drug Synergism | 1 | 1989 | 306 | 0.020 |
Why?
|
Eicosanoic Acids | 1 | 1988 | 2 | 0.020 |
Why?
|
Lipoxygenase | 1 | 1988 | 8 | 0.020 |
Why?
|
SRS-A | 1 | 1988 | 27 | 0.020 |
Why?
|
Cell Communication | 1 | 1989 | 199 | 0.020 |
Why?
|
Platelet Activating Factor | 1 | 1988 | 53 | 0.020 |
Why?
|
Superoxides | 1 | 1988 | 74 | 0.020 |
Why?
|
Serotonin | 1 | 1988 | 221 | 0.020 |
Why?
|
Sulfonamides | 1 | 1989 | 318 | 0.020 |
Why?
|
Echinocandins | 1 | 2005 | 5 | 0.020 |
Why?
|
Internationality | 1 | 2005 | 69 | 0.020 |
Why?
|
Blood Pressure | 1 | 1989 | 900 | 0.020 |
Why?
|
Placebos | 1 | 2004 | 214 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 200 | 0.010 |
Why?
|
Kidney | 1 | 1989 | 1147 | 0.010 |
Why?
|
Oxygen | 1 | 1988 | 743 | 0.010 |
Why?
|
Hemorrhage | 1 | 2004 | 280 | 0.010 |
Why?
|
Rats | 1 | 1989 | 4041 | 0.010 |
Why?
|
Kinetics | 1 | 2004 | 1528 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 374 | 0.010 |
Why?
|
Filgrastim | 1 | 1999 | 57 | 0.010 |
Why?
|
Problem Solving | 1 | 1998 | 54 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1998 | 135 | 0.010 |
Why?
|
Acridine Orange | 1 | 1996 | 2 | 0.010 |
Why?
|
Ethidium | 1 | 1996 | 13 | 0.010 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1996 | 49 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1996 | 130 | 0.010 |
Why?
|
Cell Size | 1 | 1996 | 69 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1996 | 511 | 0.010 |
Why?
|
HIV Seronegativity | 1 | 1995 | 13 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 1996 | 428 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 1 | 1995 | 59 | 0.010 |
Why?
|
Adenosine Kinase | 1 | 1994 | 1 | 0.010 |
Why?
|
Tubercidin | 1 | 1994 | 1 | 0.010 |
Why?
|
Blood Physiological Phenomena | 1 | 1994 | 9 | 0.010 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 1994 | 6 | 0.010 |
Why?
|
Scintillation Counting | 1 | 1994 | 5 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1996 | 691 | 0.010 |
Why?
|
Dipyridamole | 1 | 1994 | 14 | 0.010 |
Why?
|
Coronary Thrombosis | 1 | 1994 | 14 | 0.010 |
Why?
|
Theophylline | 1 | 1994 | 33 | 0.010 |
Why?
|
Plasma | 1 | 1994 | 51 | 0.010 |
Why?
|
Adenosine Deaminase | 1 | 1994 | 20 | 0.010 |
Why?
|
Cell Survival | 1 | 1996 | 983 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1994 | 198 | 0.010 |
Why?
|
Psychometrics | 1 | 1995 | 330 | 0.010 |
Why?
|
Erythrocytes | 1 | 1994 | 254 | 0.010 |
Why?
|
Aspirin | 1 | 1994 | 159 | 0.010 |
Why?
|
Coronary Vessels | 1 | 1994 | 190 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1994 | 1057 | 0.010 |
Why?
|
Glioblastoma | 1 | 1994 | 265 | 0.010 |
Why?
|
Cohort Studies | 1 | 1998 | 2872 | 0.010 |
Why?
|
Oxidative Stress | 1 | 1994 | 458 | 0.010 |
Why?
|
DNA | 1 | 1996 | 1308 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 1995 | 2758 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 1994 | 2366 | 0.000 |
Why?
|
Prostatic Neoplasms | 1 | 1994 | 1769 | 0.000 |
Why?
|